nodules decreased rapidly over 4 weeks. No nodules were detectable on conventional chest radiography at the 4-week follow-up. Prednisolone was reduced stepwise to 10 mg/d. During a 6-month follow-up, there was no evidence of the reoccurrence of symptoms or of pyoderma manifestations.
Discussion
Since its first description by Brunsting et al 1 in 1930, pyoderma gangrenosum has been reported in association with various systemic diseases with basic immunologic disorders, such as ulcerative colitis, Crohn's disease, polyarthritis, vasculitis, lymphoma, paraproteinemia, leukemia, or active chronic hepatitis. 2 The patient presented here showed immunologic abnormalities (ie, positive results of tests for antinuclear autoantibodies without the manifestation of other clinical complications except pulmonary nodules). Pulmonary manifestations in pyoderma gangrenosum are rare. With one exception, 3 pulmonary disease in association with pyoderma gangrenosum occurred as a single unilateral opacity on a chest radiograph. 4 -6 Kasuga et al 3 were the first authors to report a patient with multiple pulmonary nodules in association with pyoderma gangrenosum. In this particular case, the nodules were solid and were located in the peripheral portions of the lung.
The finding of multiple pulmonary nodules with central necrosis in both lungs in association with pyoderma gangrenosum has not yet been described. Histologic examination of the pulmonary manifestations of pyoderma gangrenosum revealed aseptic inflammatory lesions similar to the findings presented here. As reported earlier, the pulmonary lesions rapidly decreased with steroid therapy.
In our patient, the histologic findings of the skin biopsy corresponded closely to the findings of the lung biopsy. CT-guided biopsies of lung lesions have a very high sensitivity and specificity. In a study by Belfiore et al, 7 the cytologic diagnosis of CT-guided, fine-needle biopsy was confirmed in all 267 patients who underwent surgical or clinical follow-up. The ideal evaluation of these necrotic lung lesions would have been the acquisition of larger pieces of tissue (eg, by surgical lung biopsy). However, the patient refused this procedure and only gave consent for CT-guided, fine-needle biopsy.
With regard to the central necrotic pulmonary nodules detected on the CT scan, the most favorable radiologic diagnosis would have been Wegener's granulomatosis. However, Wegener's granulomatosis as well as septic emboli, sarcoidosis, tuberculosis, and metastatic malignant disease were ruled out by histologic and clinical findings.
In patients with pyoderma gangrenosum with the presence of radiologically visible multiple central necrotic pulmonary nodules, a pulmonary manifestation of the underlying disease should be considered 
References

T
he HIV type 1 is estimated to infect Ͼ 1 million individuals in the United States. 1 Sarcoidosis, a disease of unknown etiology, has an estimated prevalence of 10 to 80 per 100,000. 2 The hallmark of HIV infection is the destruction of CD4 ϩ T cells, which predisposes to the development of opportunistic infections. 1 In contrast, sarcoidosis is characterized by a high CD4/CD8 ratio in affected tissues, which is thought to represent a dysfunctional immune response to an unidentified antigen or antigens leading to granuloma formation. 3 HIV infection and sarcoidosis are relatively common in the same age group, yet the coexistence of the two disorders in the same individual is unusual. 4 The granulomas of sarcoidosis are rich in CD4 ϩ T lymphocytes. The relative lack of CD4 ϩ T lymphocytes in HIV disease has been offered as the explanation for the rarity of coexistent sarcoidosis and HIV infection. Recently, the occurrence of a granulomatous pulmonary disorder in two HIV-infected patients receiving highly active antiretroviral therapy (HAART) has been described. 5 We report two patients with a history of previous sarcoidosis that had remitted, who later in life contracted HIV infection and developed recurrent, progressive pulmonary sarcoidosis coincident with reconstitution of the CD4 ϩ lymphocytes while receiving HAART.
Case Reports
Case 1
A 50-year-old African-American woman with AIDS was evaluated in September 1998 for shortness of breath, fatigue, fevers, and an abnormal chest radiograph. Sarcoidosis was diagnosed 15 years before. At that time, she presented with abnormal liver function test results. Liver biopsy showed noncaseating granulomas, and she had a positive result on Kveim-Siltzbach test. Her chest radiograph was normal. She received no therapy for sarcoidosis. In April 1996, she presented with Pneumocystis carinii pneumonia (PCP), at which time she was found to be HIV positive with a CD4 cell count of 178/L. In May 1996, she was started on HAART (zidovudine, 200 mg tid; lamivudine, 150 mg bid; and indinavir, 800 mg tid). By September 1997, she was well and her chest radiograph was normal. In June 1998, she experi- 
Case 2
A 64-year-old African-American man with HIV infection and a history of sarcoidosis presented with progressive dyspnea on exertion. As a young adult, a routine chest radiograph had revealed a right lower lobe infiltrate. The diagnosis of sarcoidosis was made by open lung biopsy. He had no symptoms and received no therapy. His chest radiograph reverted to normal. He recently received a diagnosis of HIV infection and is now receiving HAART (didanosine, 150 mg bid; stavudine, 30 mg bid; and nevirapine, 200 mg bid).
On presentation, his O 2 saturation decreased from 96 to 87% with minimal exercise. Bilateral rales were heard. Laboratory studies revealed mild anemia. His CD4 cell count was 371/L with no detectable viral RNA. Chest radiograph was remarkable for bilateral pulmonary infiltrates (Fig 1) confirmed by CT. Pulmonary function tests revealed restrictive ventilatory defect with reduced diffusing capacity ( Table 1) . Fiberoptic bronchoscopy with biopsy revealed epitheloid, nonnecrotizing granulomas. Special stains and cultures of bronchial washing fluid and tissue section specimens failed to detect mycobacteria, fungi, viral pathogens, PCP, or other opportunistic infections. With the diagnosis of recurrent pulmonary sarcoidosis established, treatment was initiated with prednisone, 30 mg/d. The patient reported marked improvement in his respiratory status. Chest radiograph later demonstrated significant resolution of the pulmonary abnormalities (Fig 2) . The results of pulmonary function testing 4 months later were normal (Table 1) .
Discussion
Helper CD4
ϩ T cells are the main target of HIV infection. These cells play a central role in the formation of sarcoidosis granulomas. At the beginning of the HIV epidemic, the two diseases were thought to be mutually exclusive, based on the hypothesis that the decrease or absence of CD4 ϩ cells might inhibit the development of sarcoidosis, or prevent flare of the disease. However, several patients with concomitant HIV infection and sarcoidosis have been reported. 4 -10 In these reports, HIV infection was diagnosed before, after, or at the same time as sarcoidosis. The degree of immunosuppression by HIV infection was variable. Sarcoidosis in these patients resembled the disease affecting non-HIV infected individuals. The clinical spectrum ranged from asymptomatic presentation to multiple organ system involvement. Two patients with coexisting sarcoidosis and HIV infection who developed a positive reaction to Kveim-Siltzbach suspension were reported in 1992. 7 Suppressive HIV therapy with HAART has been associated with prolonged inhibition of viral replication and increased CD4 ϩ cell counts. 11 These quantitative changes are also associated with qualitative improvement in the host immune responses, characterized by a dramatically reduced risk of opportunistic infections. However, the resultant immune reconstitution may cause exacerbation of other, lymphocyte-dependent diseases. Symptomatic hepatitis C virus 12 as well as the paradoxical clinical progression of tuberculosis 13 have been reported in HIVinfected patients receiving HAART therapy. A prominent inflammatory response consisting of focal lymphadenitis has been described in HIV-infected patients with previous subclinical Mycobacterium avium complex infection after successful treatment with indinavir. 14 The development of "sarcoid-like" pulmonary granulomatous disease was reported in two HIV-infected patients receiving HAART. 5 The CD4 cell count of these two patients were 219/L and 318/L, respectively, with RNA levels Ͻ 500 copies/mL. The presenting chest radiographs revealed diffuse bilateral infiltrates. Transbronchial biopsies revealed noncaseating granulomas in both cases. Examination of BAL fluid and tissue section specimens failed to detect infectious or malignant processes. These patients had no history of sarcoidosis. Both patients responded to steroid therapy.
We report two patients with a history of remote sarcoidosis, who later in life contracted HIV infection and subsequently developed recurrent, progressive pulmonary sarcoidosis while receiving successful treatment with HAART. The initial diagnosis of sarcoidosis was established Ͼ 15 years prior to presentation in both cases. They were asymptomatic, had received no therapy for sarcoidosis, and their chest radiographs were considered normal at least 1 year prior to presentation. One of the patients suffered several episodes of opportunistic infections as a result of HIV infection; the other patient had limited immunosuppression. They both responded to HAART; the CD4 counts at the time of recurrent sarcoidosis were 250/L and 371/L, respectively, with no Recurrence of sarcoidosis after immunologic reconstitution with HAART offers the opportunity of better understanding the pathogenesis of sarcoidosis. Most sarcoidosis patients have spontaneous resolution of their disease with no recurrent symptoms or radiographic abnormalities later in life. 15 Many of these patients lose their ability to react to the Kveim-Siltzbach antigen, suggesting that they lack any "immunological memory" of the initial disease. In contrast, our two cases suggest that these patients do retain a group of functionally competent, "memory-type" immune cells that can be stimulated years after disease remission. The target of antiretroviral therapy is the CD4 ϩ cell population. The quality and the origin of the newly appearing CD4 ϩ cells, however, are still unknown. 11, 16 Careful analysis of the lymphocytes in patients with a remote history of sarcoidosis and HIV infection who develop recurrent sarcoidosis with HAART therapy may bring us closer to the understanding of the pathogenesis of sarcoidosis.
HIV-infected patients frequently present with respiratory distress and bilateral pulmonary infiltrates. Many of these patients today receive empiric therapy for PCP and community-acquired pneumonia without undergoing further diagnostic tests. Diffuse, progressive pulmonary sarcoidosis may develop in this population once HAART is initiated and the CD4 cell counts increase. Since granuloma formation may be the result of many common infections, the diagnosis of sarcoidosis is difficult in this population. When there is no prompt response to empiric treatment, fiberoptic bronchoscopy with biopsy is indicated to establish the specific cause of the radiographic abnormalities. Sarcoidosis should be added to the differential diagnosis in this population.
